
Crinetics Pharmaceuticals (NASDAQ:CRNX) Earns Overweight Rating from Cantor Fitzgerald
Cantor Fitzgerald restated their overweight rating on shares of Crinetics Pharmaceuticals (NASDAQ:CRNX – Free Report) in a research report report published on Monday, Benzinga reports. They currently have a $50.00 price objective on the stock. Other …